Cargando…
Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration
To describe and compare systemic and local pharmacokinetics (PK) and cervicovaginal (CV) pharmacodynamics (PD) of oral tenofovir disoproxil fumarate (TDF) in combination with emtricitabine (FTC) with tenofovir (TFV) intravaginal ring (IVR). DESIGN: Phase I, randomized, parallel-group study. Women (n...
Autores principales: | Ouattara, Louise A., Thurman, Andrea R., Jacot, Terry A., Cottrell, Mackenzie, Sykes, Craig, Blake, Kimberly, Fang, Xi, Ju, Susan, Vann, Nikolas C., Schwartz, Jill, Doncel, Gustavo F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647693/ https://www.ncbi.nlm.nih.gov/pubmed/34878438 http://dx.doi.org/10.1097/QAI.0000000000002820 |
Ejemplares similares
-
Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring
por: Thurman, Andrea R., et al.
Publicado: (2022) -
The importance of PrEP persistence in preventing HIV infections on PrEP
por: Spinelli, Matthew A, et al.
Publicado: (2020) -
“PrEP”ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women
por: Pasipanodya, Elizabeth C., et al.
Publicado: (2021) -
PrEP-RN: Clinical Considerations and Protocols for Nurse-Led PrEP
por: O'Byrne, Patrick, et al.
Publicado: (2019) -
1287. PrEP-Engaged or PrEP Curious?: A Characterization and Comparison of Initial PrEP Appointment Attenders vs. Nonattenders
por: Kahal, Deborah A, et al.
Publicado: (2019)